Table 2.
Multivariable Cox proportional hazard analysis on Overall survival and event free survival of patients with multiple myeloma.
| Characteristics | Overall survival | Event free survival | ||||
|---|---|---|---|---|---|---|
| P value | HR (95% CI) | P value | HR (95% CI) | |||
| ARPC5 | 0.02 | 1.356 | (1.05–1.75) | 0.006 | 1.351 | (1.092–1.672) |
| Age | 0.271 | 1.01 | (0.992–1.028) | 0.633 | 0.996 | (0.982–1.011) |
| Sex | 0.515 | 1.125 | (0.79–1.602) | 0.274 | 1.176 | (0.879–1.572) |
| Type | 0.884 | 0.023 | ||||
| Type (1) | 0.889 | 1.153 | (0.157–8.481) | 0.143 | 0.415 | (0.128–1.348) |
| Type (2) | 0.995 | 1.006 | (0.136–7.45) | 0.168 | 0.435 | (0.133–1.42) |
| Type (3) | 0.887 | 0.863 | (0.113–6.582) | 0.019 | 0.231 | (0.068–0.789) |
| Type (4) | 0.955 | <0.0001 | (<0.0001–<0.00001) | 0.034 | 0.085 | (0.009–0.835) |
| B2M | <0.0001 | 1.098 | (1.056–1.142) | <0.0001 | 1.088 | (1.05–1.127) |
| CRP | 0.489 | 0.997 | (0.988–1.006) | 0.489 | 0.997 | (0.99–1.005) |
| Creatinine | 0.262 | 0.917 | (0.788–1.067) | 0.604 | 0.965 | (0.845–1.103) |
| LHD | <0.0001 | 1.005 | (1.003–1.007) | 0 | 1.004 | (1.002–1.006) |
| ALB | 0.06 | 0.747 | (0.552–1.012) | 0.407 | 0.900 | (0.701–1.155) |
| HGB | 0.892 | 1.008 | (0.904–1.123) | 0.38 | 0.959 | (0.873–1.053) |
| ASPC | 0.797 | 0.999 | (0.989–1.009) | 0.413 | 0.997 | (0.988–1.005) |
| BMPS | 0.875 | 1.001 | (0.991–1.01) | 0.711 | 1.001 | (0.994–1.009) |
| MRI | 0.076 | 1.010 | (0.999–1.02) | 0.279 | 1.005 | (0.996–1.015) |
| CA | 0.001 | 0.549 | (0.388–0.777) | 0.003 | 0.645 | (0.483–0.863) |
| RACE | 0.846 | 0.948 | (0.554–1.623) | 0.116 | 1.482 | (0.908–2.420) |
| Treatment | 0.32 | 1.244 | (0.809–1.913) | 0.004 | 1.691 | (1.178–2.428) |
CRP – C-reactive protein; LDH – lactate dehydrogenase; ALB – albumin; HGB – haemoglobin; ASPC – aspirate plasma cells; BSPC – bone marrow biopsy plasma cells; CA – vytogenetic abnormalities.